Yes, cohort 2 is complete so the analysis should include all six patients. The safety check was 21 days after the first dose (at midpoint of trial). I expect to see the efficacy data next week.

"Cellceutix projects that an interim analysis of the second cohort will be completed in approximately two weeks. The trial is anticipated to be completed in 2Q2017."

http://www.cellceutix.com/press-release/2017/...8lelciljue

The immediate advancement to the third cohort tells me that B-UP was safe in the second cohort. Cohort 3 enrollment shouldn't be a problem.

"There is significant interest by new patients wishing to participate in the third (final) cohort once enrollment opens."

http://www.cellceutix.com/press-release/2017/...d-outcomes